Brian Paugh, PA
Physician Assistant · Sioux City, IANPI 1225430416
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.3% of the total across 465 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 11.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,956 and has fallen 57.1% since, to $840 in 2025. Among physician assistant clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 465 payments — averaging $14.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$789
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$769
- Teva Pharmaceuticals USA, Inc.$739
- Vanda Pharmaceuticals Inc.$721
- Supernus Pharmaceuticals, Inc.$690
- Lundbeck LLC$497
- plus $3K from 22 others
What the payments were for
- Food & beverage$6,63996%
- Education$2544%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 64 | $789 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 58 | $769 |
| Teva Pharmaceuticals USA, Inc. | 34 | $739 |
| Vanda Pharmaceuticals Inc. | 31 | $721 |
| Supernus Pharmaceuticals, Inc. | 54 | $690 |
| Lundbeck LLC | 29 | $497 |
| Neurocrine Biosciences, Inc. | 35 | $469 |
| Johnson & Johnson | 28 | $363 |
| Otsuka America Pharmaceutical, Inc. | 18 | $278 |
| Alkermes, Inc. | 15 | $226 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $221 |
| Ironshore Pharmaceuticals Inc. | 17 | $194 |
| Idorsia Pharmaceuticals US Inc | 14 | $167 |
| Sunovion Pharmaceuticals Inc. | 8 | $129 |
| Indivior Inc. | 5 | $81 |
| Corium, LLC | 10 | $81 |
| Tris Pharma Inc | 3 | $67 |
| Eisai Inc. | 4 | $60 |
| Almatica Pharma LLC | 3 | $58 |
| Neos Therapeutics, LP | 3 | $56 |
| Merck | 4 | $53 |
| Collegium Pharmaceutical, Inc. | 3 | $43 |
| Jazz Pharmaceuticals Inc. | 3 | $43 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Neuronetics, Inc. | 2 | $27 |
| Bausch Health US, LLC | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $14 |
| Adlon Therapeutics L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$292
How this compares
$6,893 in reported general payments places this provider in the 95th percentile of 1,140 physician assistant providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 13 | $147,365 |
| VraylarCariprazine Hcl | 54 | $53,156 |
| CaplytaLumateperone Tosylate | 13 | $34,644 |
| TrintellixVortioxetine Hydrobromide | 39 | $22,140 |
| Vilazodone Hcl | 43 | $4,099 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 49 | $2,881 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 88 | $2,586 |
| Bupropion XlBupropion Hcl | 120 | $2,260 |
| Quetiapine Fumarate | 54 | $1,294 |
| Divalproex Sodium ErDivalproex Sodium | 21 | $1,286 |
| Trazodone Hcl | 112 | $1,166 |
| Aripiprazole | 61 | $1,162 |
| Lorazepam | 87 | $970 |
| Duloxetine Hcl | 82 | $826 |
| Methylphenidate Hcl | 27 | $811 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $739 | $147,36513 claims |
| AbbVieVraylar | $789 | $53,15654 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $769 | $34,64413 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $221 | $22,14039 claims |
| Almatica Pharma LLCSertraline Hcl | $58 | $26658 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,140 physician assistant providers in Iowa.
Other physician assistant in Sioux City
- Albert OkineSioux City$5K
- Colette DemossSioux City$3K
- Jayson GesulgaUrbandale$878K
- Laurie ClairJohnston$293K
- Katherine LemAmes$224K
- Laura CunninghamWest Des Moines$128K
- Michon LeddyClive$73K
- Kyle HawkinsIowa City$42K
- Andrew MetzgerIowa City$37K
- Myrl HolidaIowa City$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.